References
- Annual Survey Report, 1980–83, U.S. Pharmaceutical Industry. Pharmaceutical Manufacturers Association, Washington, DC 1984; 24–39
- Bakke O. M., Wardell W. M., Lasagna L. Drug Discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of Safety. Clin. Pharm. Therap. 1984; 35: 559
- Bezold C. The Future of Pharmaceuticals. The Changing Environment for New Drugs. John Wiley and Sons, New York 1981; 46
- Clin. Pharm. Therap. 48
- Billups S. M., Billups N. F. American Drug Index. J.B. Lippincott Co., Philadelphia, PA, 1980–1985
- Bober H. personal communication and de Haen, P., New Product Survey, de Haen International. Englewood, CO Inc. 1985
- Cox W. E. Product Life Cycle as Marketing Models. The J. Bus. (Chicago) 1967; 40: 375
- Facts and Comparisons D -List. J.B. Lippincott Co., St. Louis, MO, 1980–1985
- Hansen R. W. “The Pharmaceutical Development Process: Estimates of Current Costs and Times and Effects of Regulatory Changes. Paper GPB. July, 1978. University of Rochester Center for Research in Government Policy and Business, 77–10, as revised
- Hass A. E., Jr, Portale D. B., Grossman R. E. New Drugs: Their Market Life and Safety. The Pharm. J. 1985; 234: 235
- Norwood G. J. An Analysis of New Product FAilures in the Pharmaceutical Industry Including an Econometric Evaluation of the Influence of Promotional and Research and Development Expenditure on Pharmaceutical Sales, a Ph.D. Dissertation. University of Mississippi, University, Mississippi 1970
- Prescription Drug Industry Fact Book. Pharmaceutical Manufacturers Association, Washington, DC 1980; 22–32
- Sheppard A. H. Product Innovation -A Cause for Concern. Med. Mark. Media 1979; 14: 30